Literature DB >> 29950306

Matrix abnormalities in pulmonary fibrosis.

Chandak Upagupta1, Chiko Shimbori1, Rahmah Alsilmi1, Martin Kolb1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive disease, marked by excessive scarring, which leads to increased tissue stiffness, loss in lung function and ultimately death. IPF is characterised by progressive fibroblast and myofibroblast proliferation, and extensive deposition of extracellular matrix (ECM). Myofibroblasts play a key role in ECM deposition. Transforming growth factor (TGF)-β1 is a major growth factor involved in myofibroblast differentiation, and the creation of a profibrotic microenvironment. There is a strong link between increased ECM stiffness and profibrotic changes in cell phenotype and differentiation. The activation of TGF-β1 in response to mechanical stress from a stiff ECM explains some of the influence of the tissue microenvironment on cell phenotype and function. Understanding the close relationship between cells and their surrounding microenvironment will ultimately facilitate better management strategies for IPF.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29950306     DOI: 10.1183/16000617.0033-2018

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  50 in total

1.  COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence.

Authors:  Chen-Yu Zhang; Jia-Xi Duan; Hui-Hui Yang; Chen-Chen Sun; Wen-Jing Zhong; Jia-Hao Tao; Xin-Xin Guan; Hui-Ling Jiang; Bruce D Hammock; Sung Hee Hwang; Yong Zhou; Cha-Xiang Guan
Journal:  FEBS J       Date:  2019-11-08       Impact factor: 5.542

2.  Multi-scale models of lung fibrosis.

Authors:  Julie Leonard-Duke; Stephanie Evans; Riley T Hannan; Thomas H Barker; Jason H T Bates; Catherine A Bonham; Bethany B Moore; Denise E Kirschner; Shayn M Peirce
Journal:  Matrix Biol       Date:  2020-05-11       Impact factor: 11.583

Review 3.  Defining the versican interactome in lung health and disease.

Authors:  Fengying Tang; Jourdan E Brune; Mary Y Chang; Stephen R Reeves; William A Altemeier; Charles W Frevert
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-01       Impact factor: 5.282

4.  Collagen VI Deficiency Results in Structural Abnormalities in the Mouse Lung.

Authors:  Jared A Mereness; Soumyaroop Bhattacharya; Yue Ren; Qian Wang; Christopher S Anderson; Kathy Donlon; Andrew M Dylag; Jeannie Haak; Alessia Angelin; Paolo Bonaldo; Thomas J Mariani
Journal:  Am J Pathol       Date:  2019-12-13       Impact factor: 4.307

5.  Nogo-B promotes epithelial-mesenchymal transition in lung fibrosis via PERK branch of the endoplasmic reticulum stress pathway.

Authors:  Ying Zhu; Meng Yang; Xue-Hui Li; Wu-Jian Xu; Wei Gao; Yu-Han Chen; Jian-Dong Li; Qiang Li
Journal:  Ann Transl Med       Date:  2021-04

6.  Circular RNA Methylation: A New Twist in Lung Fibrosis.

Authors:  Giovanni Ligresti; Tho X Pham; Yan Y Sanders
Journal:  Am J Respir Cell Mol Biol       Date:  2022-05       Impact factor: 6.914

7.  Following historical "tracks" of hair follicle miniaturisation in patterned hair loss: Are elastin bodies the forgotten aetiology?

Authors:  D Hugh Rushton; Gillian E Westgate; Dominique J Van Neste
Journal:  Exp Dermatol       Date:  2021-06-11       Impact factor: 4.511

Review 8.  Pathophysiological Roles of Stress-Activated Protein Kinases in Pulmonary Fibrosis.

Authors:  Yoshitoshi Kasuya; Jun-Dal Kim; Masahiko Hatano; Koichiro Tatsumi; Shuichi Matsuda
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

Review 9.  COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.

Authors:  Joowon Yim; Hee Hyun Lim; Youngjoo Kwon
Journal:  Arch Pharm Res       Date:  2021-05-28       Impact factor: 6.010

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.